The value creation plan for a PE-backed European specialty pharma included inorganic topline growth through a $100M acquisition of 15 products across 50 countries.

See how we helped them fast-track post-merger integration to capture $100m+ additional topline and 2X the expected bottom line improvements

A PE firm set out to drive growth at its newly acquired generics company. But Covid-era stockpiling and an overstretched cash conversion cycle choked cash flow and stalled value creation.

See how we helped the company pivot quickly to unlock trapped cash and sustainably improve the bottom‑line so that it could self-fund its ambitious plans for growth and preserve its earnings quality ready for exit. 

A PE consortium had a top strategy firm’s value creation plan (VCP) for its new generics acquisition. But it needed to smoothly execute the plan and significantly improve the top and bottom-lines, EBITDA, and valuation before exit. 

See how we partnered across them and the portfolio company to pragmatically execute the plans and realize the full value.

To expand its footprint in China, a clinical stage biotech needed to transform its scientific expertise and market knowledge into a corporate strategy that would secure board approval and PE funding. 

See how we partnered to prioritize asset development based on revenue and market potential and to develop a board and investor ready corporate strategy.

For a PE owned start-up in neuroscience biopharma, its ‘virtual’ business model relied heavily on CROs and third-party providers. But it needed the procurement infrastructure to enter into initial critical supplier agreements. 

See how we partnered with this porfolio company to design its procurement organization and co-create and codify its modus operandi and processes.